[Variations of the immunological parameters and the clinical response in 25 children treated with thymopentin].
We studied the effects of thymopentin on 25 children aged between 15 months and 11 years, suffering from relapsing herpes, malnutrition and recurrent infections of respiratory tract. None of these children had previously received vaccines or immunostimulating drugs. Our purpose was to test thymopentin efficacy on various pathologies. We carried out a series of blood tests before, during and after drug administration in order to evaluate the variations of immunological parameters (IgA, IgG, IgM, IgAs, C3, C4 and cellular immunity), as well as changes in weight and height. Thymopentin was administered at a dose of 0.5 mg/Kg three times a week for three weeks. Seric IgA (Tab. 2) were also affected by thymopentin. As far as cellular immunity is concerned we observed a progressive increase of CD3 and CD8 during thymopentin treatment. Tolerability was excellent. Only one child had a slight fever that disappeared at the end of treatment. No hematological disorders were reported.
Melaranci
C
C
II Divisione, Ospedale Pediatrico Bambino Gesù, Italia.
Giammaria
P
P
D002648:Child; D002675:Child, Preschool; D003165:Complement System Proteins / Q000032:analysis; D004341:Drug Evaluation; D006561:Herpes Simplex / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007109:Immunity / Q000187:drug effects* / Q000276:immunology; D007136:Immunoglobulins / Q000097:blood; D007223:Infant; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D009748:Nutrition Disorders / Q000188:drug therapy / Q000276:immunology; D012008:Recurrence; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000276:immunology; D016305:Thymopentin / Q000627:therapeutic use*
D007136:Immunoglobulins; D003165:Complement System Proteins; D016305:Thymopentin
Variazioni dei parametri immunologici e risposta clinica in 25 bambini trattati con timopentina.